DT
DTRK.US DATATRAK International Inc
- Market cap
- USD 8.03M
- P/E
- -
- P/B
- -
- ROE
- 42.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is DTRK.US undervalued?
Graham numberThe Graham number of DATATRAK International Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
DATATRAK International Inc fundamental analysis
No fundamental analysis for DATATRAK International Inc yet.
DATATRAK International Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About DATATRAK International Inc
DATATRAK International, Inc., a technology and services company, provides unified clinical solutions and related services for the clinical trials industry. The company offers DATATRAK ONE Unified Experience, a clinical enterprise solution that allows clinical users and service providers to design, deliver, and manage clinical trials. Its products include UX CTMS 360 for planning and managing trials; UX Trial to streamline design-to-deployment process using a tool; UX EDC & M…
Full company profileDATATRAK International Inc financial statements
DATATRAK International Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 8.98M | 7.52M | 7.45M | 7.74M | 7.16M | 6.38M | 5.93M | 6.18M | 6.69M | 7.19M |
| Gross Profit | 7.13M | 5.50M | 5.37M | 5.52M | 5.22M | 4.18M | 3.68M | 5.15M | 5.46M | 5.84M |
| Operating Income | 1.08M | 212K | 161K | 374K | -90.1K | -1.15M | -1.48M | 1.88M | 2.00M | 2.11M |
| EBITDA | 1.34M | 850K | 842K | 1.44M | 683K | 626K | -1.04M | 2.73M | 11.5M | 2.17M |
| Net Income | 1.02M | 220K | 162K | 387K | -90.2K | -250K | -889K | 2.66M | 11.4M | 2.68M |
| EPS | 0.55 | 0.11 | 0.07 | 0.16 | -0.04 | -0.10 | -0.32 | 0.63 | 0.33 | 0.06 |
| Balance Sheet | ||||||||||
| Total Assets | 5.27M | 5.51M | 5.28M | 8.37M | 8.23M | 6.35M | 5.74M | 4.32M | 15.6M | 13.9M |
| Total Liabilities | 7.27M | 5.42M | 4.77M | 7.23M | 6.97M | 5.16M | 4.47M | 6.18M | 7.25M | 7.61M |
| Shareholders' Equity | -2.00M | 86.8K | 505K | 1.15M | 1.26M | 1.19M | 1.32M | -1.86M | 8.32M | 6.30M |
| Cash & Short-term Investments | 2.47M | 2.54M | 2.36M | 4.00M | 2.64M | 1.70M | 636K | 167K | 1.16M | 1.01M |
| Total Debt | 870K | 46.2K | 45.8K | 1.91M | 2.73M | 1.08M | 750K | 267K | 25.4K | 21.0K |
| Cash Flow | ||||||||||
| Operating Cash Flow | 1.24M | 158K | 460K | 2.42M | -1.35M | 286K | -2.75M | 3.72M | 1.83M | 857K |
| Capital Expenditure | 936K | 530K | 596K | 713K | 743K | 753K | 8.51M | 333K | 566K | 701K |
| Free Cash Flow | 302K | -372K | -136K | 1.71M | -2.10M | -466K | -11.3M | 3.39M | 1.26M | 156K |
| Ratios | ||||||||||
| ROE | - | 253.2% | 32.0% | 33.7% | -7.1% | -21.1% | -67.6% | - | 137.3% | 42.6% |
| ROA | 19.3% | 4.0% | 3.1% | 4.6% | -1.1% | -3.9% | -15.5% | 61.5% | 73.4% | 19.3% |
| Net Profit Margin | 11.3% | 2.9% | 2.2% | 5.0% | -1.3% | -3.9% | -15.0% | 43.0% | 171.0% | 37.3% |
| Debt to Equity | - | 0.53x | 0.09x | 1.66x | 2.17x | 0.91x | 0.57x | - | 0.00x | 0.00x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
DATATRAK International Inc dividends
DATATRAK International Inc has not paid dividends in the last 10 fiscal years.
Last stock split: 1:12 on Jun 4, 2013.
Who owns DATATRAK International Inc
- Insiders 0.00%
- Institutions 76.05%
- Public & others 23.95%
- Shares outstanding 27.7M
DATATRAK International Inc company profile
- Company name
- DATATRAK International Inc
- Ticker
- DTRK.US
- Exchange
- USA Stocks
- Listed since
- Jun 11, 1996
- Sector
- Healthcare
- Industry
- Health Care Technology
- Fiscal year end
- December
- Address
- 5900 Landerbrook Drive, Mayfield Heights, OH, United States, 44124
- Phone
- 440 443 0082
- Website
- fountayn.com
About DATATRAK International Inc
DATATRAK International, Inc., a technology and services company, provides unified clinical solutions and related services for the clinical trials industry. The company offers DATATRAK ONE Unified Experience, a clinical enterprise solution that allows clinical users and service providers to design, deliver, and manage clinical trials. Its products include UX CTMS 360 for planning and managing trials; UX Trial to streamline design-to-deployment process using a tool; UX EDC & Medical Coding for capturing and delivering data; UX Randomization and Trial Supply Management to randomize patients and automate supply; UX Patient Data Capture; UX Safety; and UX Training to train users and track certificates. The company also provides DATATRAK Clinical Consulting Services, such as training, support, learning center, Software as a Service hosting, standards, and trial design services. It serves contract research organizations, pharma and biotech companies, and clinical trial device companies. DATATRAK International, Inc. was founded in 1991 and is headquartered in Mayfield Heights, Ohio.
DATATRAK International Inc management
2- Mr. Alex TabatabaiCEO & Chairman of the Board
- Mr. Sean MahoneyVice President of Operations & Strategy